Georgetown has reported the results of their Nilotinib clinical trial. They may interpret the data differently, however, the results really are quite similar to the Northwestern trial. I believe they are hopping to get support for a phase 3. I honestly think, though, that given the limited amount of research dollars available, the funds would be better used to research the other three c-abl inhibitors that are going into trial. They all have better neurological profiles than nilotinib.

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial | Movement Disorders | JAMA Neurology | JAMA Network